Clinical and research markers of oxidative stress in chronic kidney disease

Biomarkers

Volumn 18, Issue 2, 2013, Pages 103-115

  Tucker, Patrick Steven ^a   Dalbo, Vincent James ^a   Han, Thin ^b   Kingsley, Michael Ian ^c  

^a CENTRAL QUEENSLAND UNIVERSITY   (Australia)

^b Queensland Government   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

Antioxidant status; Reactive nitrogen species; Reactive oxygen species; Renal disease; Renal failure

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED OXIDATION PROTEIN PRODUCT; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; CATALASE; CHOLESTEROL ESTER; GLUTATHIONE; HOMOCYSTEINE; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MALONALDEHYDE; METHIONINE; N(G),N(G) DIMETHYLARGININE; OMEGA 3 FATTY ACID; PROTEIN CARBONYL; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOREDOXIN; UNCLASSIFIED DRUG;

CELL TRANSPORT; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; DNA CROSS LINKING; DNA DAMAGE; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; ENERGY YIELD; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; KIDNEY FUNCTION; LIPID PEROXIDATION; OXIDATIVE STRESS; POINT MUTATION; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; ARGININE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DEOXYGUANOSINE; F2-ISOPROSTANES; GLUTATHIONE; HUMANS; KIDNEY; LIPID PEROXIDATION; LIPID PEROXIDES; MALONDIALDEHYDE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84873912592     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.749302     Document Type: Review

References (184)

1. Agarwal R. (2003). Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 284:F863-9. (Pubitemid 36336992)
2. AIHW. (2007). Health expenditure Australia 2005-06.
3. Canberra: Australian Institute of Health and Welfare. AIHW. (2009). Health care expenditure on chronic kidney disease in Australia 2004-05. Canberra: Australian Institute of Health and Welfare.
4. Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, et al. (2007). Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition 23:242-7. (Pubitemid 46367571)
5. Anderson JW, Konz EC. (2001). Obesity and disease management: effects of weight loss on comorbid conditions. Obesity Res 9:326S-34S.
6. Annuk M, Fellstrom B, Akerblom O, et al. (2001a). Oxidative stress markers in pre-uremic patients. Clin Nephrol 56:308-14. (Pubitemid 32923165)
7. Annuk M, Soveri I, Zilmer M, et al. (2005). Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 18:721-6. (Pubitemid 43085438)
8. Annuk M, Zilmer M, Lind L, et al. (2001b). Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-52. (Pubitemid 33115422)
9. Antolini F, Valente F, Ricciardi D, et al. (2005). Principal component analysis of some oxidative stress parameters and their relationships in hemodialytic and transplanted patients. Clin Chim Acta 358:87-94. (Pubitemid 40966636)
10. Antolovich M, Prenzler PD, Patsalides E, et al. (2002). Methods for testing antioxidant activity. Analyst 127:183-98. (Pubitemid 34081656)
11. Apeland T, Mansoor MA, Seljeflot I, et al. (2002). Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Intern Med 252:456-64. (Pubitemid 36706577)
12. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. (1996). The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56:41-6. (Pubitemid 26064671)
13. Aslam S, Santha T, Leone A, Wilcox C. (2006). Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in endstage renal disease patients on hemodialysis. Kidney Int 70:2109-15. (Pubitemid 44871373)
14. Atalay M, Laaksonen DE, Niskanen L, et al. (1997). Altered antioxidant enzyme defences in insulin-dependent diabetic men with increased resting and exercise-induced oxidative stress. Acta Physiol Scand 161:195-201. (Pubitemid 27445703)
15. Atamer A, Kocyigit Y, Ecder SA, et al. (2008). Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol 21:924-30.
16. Aveles PR, Criminacio CR, Goncalves S, et al. (2010). Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract 116:c294-9.
17. Aygen B, Celiker H, Dogukan A, Ilhan N. (2008). The effects of trimetazidine on lipid peroxidation in patients with end-stage renal disease. Methods Find Exp Clin Pharmacol 30:757-60.
18. Baragetti I, Raselli S, Stucchi A, et al. (2007). Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. Nephrol Dial Transplant 22:3292-7. (Pubitemid 350202563)
19. Basu S. (2007). The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target. Scand J Food Nutr 51:48-61. (Pubitemid 46934154)
20. Beltrami C, Clayton A, Phillips AO, et al. (2012). Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans 40:875-9.
21. Berlett BS, Stadtman ER. (1997). Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272:20313-16. (Pubitemid 27355575)
22. Biasioli S, Schiavon R, Petrosino L, et al. (2001). Do different dialytic techniques have different atherosclerotic and antioxidant activities? ASAIO J 47:516-21. (Pubitemid 32862321)
23. Biasioli S, Schiavon R, Petrosino L, et al. (1997). Free radicals and oxidative stress challenge dialysis patients: effects of two different membranes. ASAIO J 43:M766-72. (Pubitemid 27473208)
24. Billings FTT, Ball SK, Roberts LJ, et al. (2011). Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Radic Biol Med 50:1480-7.
25. Bober J, Kedzierska K, Kwiatkowska E, et al. (2010). Does oxidative stress affect the activity of the sodium-proton exchanger? Ann Acad Med Stetin 56:5-12.
26. Bogdanov MB, Beal MF, McCabe DR, et al. (1999). A carbon columnbased liquid chromatography electrochemical approach to routine 8-hydroxy-20- deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radic Biol Med 27:647-66. (Pubitemid 29408652)
27. Bordoni V, Piroddi M, Galli F, et al. (2006). Oxidant and carbonyl stressrelated apoptosis in end-stage kidney disease: impact of membrane flux. Blood Purif 24:149-56. (Pubitemid 41820837)
28. Bostom AG, Shemin D, Verhoef P, et al. (1997). Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol 17:2554-8. (Pubitemid 28015993)
29. Bouzidi N, Mekki K, Boukaddoum A, et al. (2010). Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. J Ren Nutr 20:321-8.
30. Bowling CB, Feller MA, Mujib M, et al. (2011). Relationship between stage of kidney disease and incident heart failure in older adults. Am J Nephrol 34:135-41.
31. Burke-Gaffney A, Callister ME, Nakamura H. (2005). Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398-404 (Pubitemid 41039215)
32. Cadet J, Douki T, Ravanat JL. (2010). Oxidatively generated base damage to cellular DNA. Free Radic Biol Med 49:9-21.
33. Canestrari F, Buoncristiani U, Galli F, et al. (1995). Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin Chim Acta 234:127-36.
34. Cass A, Chadban S, Gallagher M, et al. (2010). The economic impact of end stage kidney disease in Australia: Projections to 2020. Melbourne: Kidney Health Australia.
35. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. (1996). Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21:845-53. (Pubitemid 26365280)
36. Cevat Inal T, Tuli A, Yuregir GT. (1996). Evaluation of reference values for erythrocyte glutathione. Clin Chim Acta 256:189-96. (Pubitemid 27055807)
37. Chang JW, Lee EK, Kim TH, et al. (2007). Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic endstage renal disease patients on hemodialysis: a pilot study. Am J Nephrol 27:70-4. (Pubitemid 46364543)
38. Chatterjee SR, Srivastava TS, Kamat JP, Devasagayam TP. (1997a). Lipid peroxidation induced by a novel porphyrin plus light in isolated mitochondria: possible implications in photodynamic therapy. Mol Cell Biochem 166:25-33. (Pubitemid 27085083)
39. Chatterjee SR, Srivastava TS, Kamat JP, Devasagayam TP. (1997b). Lipid peroxidation induced by meso-tetrakis[3,4-bis(carboxymethyleneoxy) phenyl] porphyrin on photosensitization in hepatic and tumor microsomes. Chem Biol Interact 108:27-37. (Pubitemid 28057415)
40. Chen J, Muntner P, Hamm LL, et al. (2004). The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-74.
41. Coaccioli S, Standoli ML, Biondi R, et al. (2010). Open comparison study of oxidative stress markers between patients with chronic renal failure in conservative therapy and patients in haemodialysis. Clin Ter 161:435-9.
42. Collins AR. (2004). The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26:249-61. (Pubitemid 41490465)
43. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. (2003). Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17:1195-214. (Pubitemid 36775767)
44. Dalle-Donne I, Giustarini D, Colombo R, et al. (2003a). Protein carbonylation in human diseases. Trends Mol Med 9:169-76. (Pubitemid 36626706)
45. Dalle-Donne I, Rossi R, Giustarini D, et al. (2003b). Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329:23-38. (Pubitemid 36187411)
46. de Cavanagh EM, Ferder L, Carrasquedo F, et al. (1999). Higher levels of antioxidant defenses in enalapril-treated versus non-enalapriltreated hemodialysis patients. Am J Kidney Dis 34:445-55. (Pubitemid 29413616)
47. de Vecchi AF, Bamonti F, Novembrino C, et al. (2009). Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. Nephrol Dial Transplant 24:2524-9.
48. Del Rio D, Stewart AJ, Pellegrini N. (2005). A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 15:316-28. (Pubitemid 41190990)
49. Domenici FA, Vannucchi MT, Jordao AA, et al. (2005). DNA oxidative damage in patients with dialysis treatment. Ren Fail 27:689-94. (Pubitemid 41748120)
50. Dounousi E, Papavasiliou E, Makedou A, et al. (2006). Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752-60. (Pubitemid 44740054)
51. Drai J, Bannier E, Chazot C, et al. (2001). Oxidants and antioxidants in long-term haemodialysis patients. Farmaco 56:463-5. (Pubitemid 32622119)
52. Eiselt J, Racek J, Opatrny Jr K. (2000). Oxidative stress: the effect of erythropoietin and the dialysis membrane. Int J Artif Organs 23:33-40. (Pubitemid 30116413)
53. Emre H, Keles M, Yildirim S, et al. (2011). Comparison of the oxidantantioxidant parameters and sialic acid levels in renal transplant patients and peritoneal dialysis patients. Transplant Proc 43:809-12.
54. Ersson C, Thorman R, Rodhe Y, et al. (2011). DNA damage in salivary gland tissue in patients with chronic kidney disease, measured by the comet assay. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:209-15.
55. Fatouros IG, Douroudos I, Panagoutsos S, et al. (2010). Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 42:1809-18.
56. Fatouros IG, Pasadakis P, Sovatzidis A, et al. (2008). Acute exercise may exacerbate oxidative stress response in hemodialysis patients. Nephron Clin Pract 109:c55-64.
57. Fragedaki E, Nebel M, Schupp N, et al. (2005). Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrol Dial Transplant 20:1936-43. (Pubitemid 41222611)
58. Fujiwara N, Nakamura T, Sato E, et al. (2011). Renovascular protective effects of erythropoietin in patients with chronic kidney disease. Intern Med 50:1929-34.
59. Furuya R, Kumagai H, Odamaki M, et al. (2009). Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 112:c255-61.
60. Gal-Moscovici A, Sprague SM. (2010). Use of vitamin D in chronic kidney disease patients. Kidney Int 78:146-51.
61. Ganji V, Kafai MR. (2006). Population reference values for plasma total homocysteine concentrations in US adults after the fortification of cereals with folic acid. Am J Clin Nutr 84:989-94. (Pubitemid 44730366)
62. Gerdemann A, Wagner Z, Solf A, et al. (2002). Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 17:1045-9. (Pubitemid 34746207)
63. Ghiadoni L, Cupisti A, Huang Y, et al. (2004). Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 17:512-19. (Pubitemid 39302878)
64. Girotti AW. (1998). Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 39:1529-42. (Pubitemid 28377917)
65. Gocmen AY, Sahin E, Kocak H, et al. (2008). Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clin Biochem 41:836-40.
66. Guemouri L, Artur Y, Herbeth B, et al. (1991). Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood. Clin Chem 37:1932-7. (Pubitemid 121000148)
67. Gugliucci A, Kotani K, Kimura S. (2012). Paraoxonase 1 in chronic kidney failure. J Lipids 2012:726048. doi: 10.1155/2012/726048.
68. Gutteridge JM, Halliwell B. (1990). The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 15:129-35. (Pubitemid 20186835)
69. Halliwell B, Chirico S. (1993). Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 57:715S-24S; discussion 724S-725S.
70. Hayes JD, Flanagan JU, Jowsey IR. (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88. (Pubitemid 40261798)
71. Himmelfarb J, Phinney S, Ikizler TA, et al. (2007). Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 17:296-304. (Pubitemid 47284905)
72. Hov GG, Sagen E, Bigonah A, Asberg A. (2007). Health-associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with highperformance liquid chromatography. Scand J Clin Lab Invest 67:868-76. (Pubitemid 350158772)
73. Hwang I, Lee J, Huh JY, et al. (2012). Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 61:728-38.
74. Ikizler TA, Morrow JD, Roberts LJ, et al. (2002). Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58:190-7. (Pubitemid 34994045)
75. Inal M, Kanbak G, Sen S, et al. (1999). Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy. Free Radic Res 31:211-16. (Pubitemid 29435883)
76. Jakubowski H. (2002). Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 277:30425-8. (Pubitemid 34970732)
77. Johnson DW, Armstrong K, Campbell SB, et al. (2007). Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 12:391-8. (Pubitemid 47075413)
78. Kaisar M, Isbel N, Johnson DW. (2007). Cardiovascular disease in patients with chronic kidney disease: a clinical review. Minerva Urol Nefrol 59:281-97. (Pubitemid 350205658)
79. Kalogerakis G, Baker AM, Christov S, et al. (2005). Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci (Lond) 108:497-506. (Pubitemid 40827557)
80. Kamat JP, Sarma HD, Devasagayam TP, et al. (1997). Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. Mol Cell Biochem 170:131-7. (Pubitemid 27182942)
81. Kamgar M, Zaldivar F, Vaziri ND, Pahl MV. (2009). Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 101:336-44.
82. Kan E, Undeger U, Bali M, Basaran N. (2002). Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of Vitamin E supplementation. Mutat Res 520:151-9. (Pubitemid 35247584)
83. Kaneda H, Taguchi J, Ogasawara K, et al. (2002). Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162:221-5. (Pubitemid 34327362)
84. Kannampuzha J, Donnelly SM, McFarlane PA, et al. (2010). Glutathione and riboflavin status in supplemented patients undergoing home nocturnal hemodialysis versus standard hemodialysis. J Ren Nutr 20:199-208.
85. Karihtala P, Soini Y. (2007). Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115:81-103. (Pubitemid 46208084)
86. Karsli Ceppioglu S, Yurdun T, Canbakan M. (2011). Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease. Ren Fail 33:866-74.
87. Keshavarzian A, Banan A, Farhadi A, et al. (2003). Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 52:720-8. (Pubitemid 36528876)
88. KHA. (2007). Chronic kidney disease (CKD) managment in general practice. Melbourne: Kidney Health Australia.
89. Kielstein JT, Boger RH, Bode-Boger SM, et al. (2002). Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13:170-6. (Pubitemid 34042024)
90. Kielstein JT, Zoccali C. (2008). Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 17:609-15.
91. Kirmizis D, Papagianni A, Belechri AM, Memmos D. (2011). Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant 26:2296-301.
92. Kohen R, Nyska A. (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 30:620-50. (Pubitemid 36018731)
93. Kuchta A, Pacanis A, Kortas-Stempak B, et al. (2011). Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res 34:12-19.
94. Kuo HT, Kuo MC, Chiu YW, et al. (2005). Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis. Eur J Clin Invest 35:245-50.
95. Lee CY, Huang SH, Jenner AM, Halliwell B. (2008). Measurement of F2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 44:1314-22.
96. Lee DM. (1999). A simple and sensitive method in using the ratios of cholesteryl ester molecular species as indexes of oxidative stress in plasma and lipoprotein fractions. Atherosclerosis 146:221-35. (Pubitemid 29418053)
97. Lee DM, Jackson KW, Knowlton N, et al. (2011). Oxidative stress and inflammation in renal patients and healthy subjects. PLoS One 6:e22360. doi: 10.1371/journal.pone.0022360.
98. Leitinger N. (2003). Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 24:239-50. (Pubitemid 36945024)
99. Lemarechal H, Allanore Y, Chenevier-Gobeaux C, et al. (2006). High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. Clin Chim Acta 367:156-61.
100. Lentini P, de Cal M, Cruz D, et al. (2010). The role of advanced oxidation protein products in intensive care unit patients with acute kidney injury. J Crit Care 25:605-9.
101. Liberati A, Altman DG, Tetzlaff J, et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. doi: 10.1136/bmj.b2700.
102. Lobo V, Patil A, Phatak A, Chandra N. (2010). Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev 4:118-26.
103. Locatelli F, Canaud B, Eckardt KU, et al. (2003). Oxidative stress in endstage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272-80. (Pubitemid 36826946)
104. Macias Nunez JF, Ghais Z, Bustamante J, et al. (2010). Evaluation of oxidant-antioxidant balance in patients on maintenance haemodialysis: a comparative study of dialyzers membranes. Nephron Clin Pract 114:c67-73.
105. Mastalerz-Migas A, Reksa D, Pokorski M, et al. (2007). Comparison of a statin vs. hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 58:363-70. (Pubitemid 351346685)
106. McCord JM, Edeas MA. (2005). SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed Pharmacother 59:139-42. (Pubitemid 40603324)
107. Mekki K, Bouzidi-Bekada N, Kaddous A, Bouchenak M. (2010). Mediterranean diet improves dyslipidemia and biomarkers in chronic renal failure patients. Food Funct 1:110-15.
108. Milne GL, Sanchez SC, Musiek ES, Morrow JD. (2007). Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2:221-6. (Pubitemid 47040087)
109. Mimic-Oka J, Simic T, Djukanovic L, et al. (1999). Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 51:233-41. (Pubitemid 29196887)
110. Minino AM, Smith BL. (2001). Deaths: preliminary data for 2000. Natl Vital Stat Rep 49:1-40.
111. Mishra V, Baines M, Perry SE, et al. (2007). Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. Clin Nutr 26:41-50. (Pubitemid 46179127)
112. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC. (2009). Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 113:c234-40.
113. Miyamoto T, Rashid Qureshi A, Yamamoto T, et al. (2011). Postprandial metabolic response to a fat-and carbohydrate-rich meal in patients with chronic kidney disease. Nephrol Dial Transplant 26:2231-7.
114. Mo JY, Maki H, Sekiguchi M. (1992). Hydrolytic elimination of a mutagenic nucleotide 8-oxodGTP, by human 18-kilodalton protein: sanitization of nucleotide pool. Proc Natl Acad Sci USA 89:11021-5.
115. Moller P. (2006). Assessment of reference values for DNA damage detected by the comet assay in human blood cell DNA. Mutat Res 612:84-104. (Pubitemid 43222095)
116. Monostori P, Hracsko Z, Karg E, et al. (2009). Erythropoiesisstimulating agent withdrawal and oxidative stress in hemodialysis. Clin Nephrol 71:521-6.
117. Morena M, Jaussent I, Chalabi L, et al. (2010). Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int 14:403-10.
118. Nakamura T, Sato E, Fujiwara N, et al. (2009). Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 60:525-8.
119. Nakamura T, Sato E, Fujiwara N, et al. (2010). Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 61:58-61.
120. Nakamura T, Sato E, Fujiwara N, et al. (2011). Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 60:260-4.
121. Nakamura T, Sato E, Fujiwara N, et al. (2012). Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci 343:46-51.
122. Nanayakkara PW, Teerlink T, Stehouwer CD, et al. (2005). Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68:2230-6. (Pubitemid 43117798)
123. Nanayakkara PW, van Guldener C, Ter Wee PM, et al. (2007). Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167:1262-70. (Pubitemid 46998497)
124. Nascimento MM, Suliman ME, Silva M, et al. (2010). Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 30:336-42.
125. Nelson SK, Bose SK, Grunwald GK, et al. (2006). The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radic Biol Med 40:341-7. (Pubitemid 43069358)
126. Neve J, Wasowicz W, Quivy D, et al. (1995). Lipid peroxidation assessed by serum thiobarbituric acid reactive substances in healthy subjects and in patients with pathologies known to affect trace element status. Biol Trace Elem Res 47:147-53.
127. Nielsen F, Mikkelsen BB, Nielsen JB, et al. (1997). Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 43:1209-14. (Pubitemid 27297265)
128. Niki E. (2009). Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 47:469-84.
129. Nolin TD, Ouseph R, Himmelfarb J, et al. (2010). Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 5:1588-94.
130. Oberg BP, Mcmenamin E, Lucas FL, et al. (2004). Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65:1009-16. (Pubitemid 38251077)
131. Ongajooth L, Ongajyooth S, Likidlilid A, et al. (1996). Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. J Med Assoc Thai 79:791-800.
132. Palleschi S, de Angelis S, Diana L, et al. (2007). Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin Chem Lab Med 45:1211-18. (Pubitemid 47396277)
133. Percy C, Pat B, Poronnik P, Gobe G. (2005). Role of oxidative stress in age-associated chronic kidney pathologies. Adv Chronic Kidney Dis 12:78-83. (Pubitemid 40255607)
134. Pergola PE, Raskin P, Toto RD, et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-36.
135. Perna AF, Ingrosso D, de Santo NG. (2003). Homocysteine and oxidative stress. Amino Acids 25:409-17. (Pubitemid 38041275)
136. Peuchant E, Delmas-Beauvieux MC, Dubourg L, et al. (1997). Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radic Biol Med 22:313-20. (Pubitemid 26399337)
137. Pryor WA. (1986). Oxy-radicals and related species: their formation, lifetimes, and reactions. Annu Rev Physiol 48:657-67. (Pubitemid 16047640)
138. Ramakrishna V, Jailkhani R. (2008). Oxidative stress in noninsulin- dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 45:41-6. (Pubitemid 351238275)
139. Ramezani M, Nazemian F, Shamsara J, et al. (2011). Effect of omega-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patients. J Ren Nutr 21:196-9.
140. Ramos R, Martinez-Castelao A. (2008). Lipoperoxidation and hemodialysis. Metabolism 57:1369-74.
141. Renke M, Tylicki L, Rutkowski P, et al. (2010). The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebocontrolled, randomized, cross-over study. Med Sci Monit 16:PI13-18.
142. Roberts 2nd LJ, Fessel JP. (2004). The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 128:173-86. (Pubitemid 38167386)
143. Roberts LJ, Morrow JD. (2000). Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 28:505-13. (Pubitemid 30136031)
144. Romeu M, Nogues R, Marcas L, et al. (2010). Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. BMC Res Notes 3:20. doi: 10.1186/1756-0500-3-20.
145. Rutkowski P, Malgorzewicz S, Slominska E, et al. (2006). Interrelationship between uremic toxicity and oxidative stress. J Ren Nutr 16:190-3. (Pubitemid 43975002)
146. Rutkowski P, Slominska EM, Szolkiewicz M, et al. (2007). Relationship between uremic toxins and oxidative stress in patients with chronic renal failure. Scand J Urol Nephrol 41:243-8. (Pubitemid 46676354)
147. Sakata T, Furuya R, Shimazu T, et al. (2008). Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif 26:371-8.
148. Saran R, Novak JE, Desai A, et al. (2003). Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 18:2415-20. (Pubitemid 37336835)
149. Satoh M, Yamasaki Y, Nagake Y, et al. (2001). Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 59:1943-50. (Pubitemid 32336811)
150. Scholze A, Rinder C, Beige J, et al. (2004). Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 109:369-74. (Pubitemid 38133906)
151. Sebekova K, Gazdikova K, Syrova D, et al. (2003). Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 17:265-70. (Pubitemid 36592018)
152. Seljeskog E, Hervig T, Mansoor MA. (2006). A novel HPLC method for the measurement of thiobarbituric acid reactive substances (TBARS). A comparison with a commercially available kit. Clin Biochem 39:947-54. (Pubitemid 44344684)
153. Shimoike T, Inoguchi T, Umeda F, et al. (2000). The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49:1030-5. (Pubitemid 30641441)
154. Shurtz-Swirski R, Mashiach E, Kristal B, et al. (1995). Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure. Nephron 71:176-9.
155. Simmons EM, Langone A, Sezer MT, et al. (2005). Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79:914-19. (Pubitemid 40586863)
156. Stepniewska J, Dolegowska B, Ciechanowski K, et al. (2006). Erythrocyte antioxidant defense system in patients with chronic renal failure according to the hemodialysis conditions. Arch Med Res 37:353-9.
157. Suehiro T, Ikeda Y, Shiinoki T, et al. (2002). Serum paraoxonase (PON1)
158. Suzuki D, Miyata T, Saotome N, et al. (1999). Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822-32. (Pubitemid 29149533)
159. Sydow K, Munzel T. (2003). ADMA and oxidative stress. Atheroscler Suppl 4:41-51. (Pubitemid 38234494)
160. Takahashi N, Morimoto S, Okigaki M, et al. (2011). Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. Nephrol Dial Transplant 26:1252-7.
161. Tarng DC, Huang TP, Liu TY, et al. (2000). Effect of vitamin E-bonded membrane on the 8-hydroxy 20-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 58:790-9.
162. Tarng DC, Liu TY, Huang TP. (2004). Protective effect of vitamin C on 8-hydroxy-20-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney Int 66:820-31.
163. Tomiyama H, Watanabe G, Yoshida H, et al. (2003). Reduction of oxidative stress augments natriuretic effect of furosemide in moderate heart failure. Am Heart J 145:E2.
164. Townsend DM, Tew KD, Tapiero H. (2003). The importance of glutathione in human disease. Biomed Pharmacother 57:145-55. (Pubitemid 36740460)
165. Tsuchikura S, Shoji T, Shimomura N, et al. (2010). Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrol 11:7. doi: 10.1186/1471-2369-11-7.
166. Usberti M, Gerardi G, Micheli A, et al. (2002). Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients. J Nephrol 15:558-64. (Pubitemid 35396521)
167. Valavanidis A, Vlachogianni T, Fiotakis C. (2009). 8-Hydroxy-20- deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27:120-39.
168. Valli A, Suliman ME, Meert N, et al. (2007). Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 379:87-94. (Pubitemid 46366973)
169. Vaziri ND. (2010). Lipotoxicity and impaired high density lipoproteinmediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr 20:S35-43.
170. Vincent HK, Morgan JW, Vincent KR. (2004). Obesity exacerbates oxidative stress levels after acute exercise. Med Sci Sports Exerc 36:772-9. (Pubitemid 38596380)
171. Vural A, Yilmaz MI, Caglar K, et al. (2005). Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 25:250-5. (Pubitemid 41202747)
172. Wang X, Desai K, Juurlin K, et al. (2006). Gender-related differences in advanced glycation endproducts, oxidative stress markers and nitric oxide synthases in rats. Kidney Int 69:281-7. (Pubitemid 43323078)
173. Williams DR. (2012). Miles to go before we sleep. J Health Soc Behav 53:279-95.
174. Wilund KR, Tomayko EJ., Wu PT, et al. (2010). Intradialytic exercise training reduces oxidative stress and epicardial fat: a pilot study. Nephrol Dial Transplant 25:2695-701.
175. Wiseman H, Halliwell B. (1996). Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313:17-29. (Pubitemid 26013419)
176. Witko-Sarsat V, Descamps-Latsch, B. (1997). Advanced oxidation protein products: novel uraemic toxins and pro-inflammatory mediators in chronic renal failure? Nephrol Dial Transplant 12:1310-12 (Pubitemid 27353014)
177. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. (1996). Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-13. (Pubitemid 26166404)
178. Yeh CC, Lai CY, Hsieh LL, et al. (2010). Protein carbonyl levels, glutathione S-transferase polymorphisms and risk of colorectal cancer. Carcinogenesis 31:228-33.
179. Yilmaz MI, Saglam M, Caglar K, et al. (2006). The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42-50. (Pubitemid 41828265)
180. Zachara BA, Gromadzinska J, Palus J, et al. (2011). The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: a pilot study. Biol Trace Elem Res 142:274-83.
181. Zelko IN, Mariani TJ, Folz RJ. (2002). Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33:337-49. (Pubitemid 34790245)
182. Zhloba AA, Blashko EL. (2004). Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 800:275-80. (Pubitemid 38041035)
183. Zima T, Stipek S, Crkovska J, et al. (1996). Lipid peroxidation and antioxidant enzymes in CAPD patients. Ren Fail 18:113-19. (Pubitemid 26073880)
184. Zoccali C, Bode-Boger S, Mallamaci F, et al. (2001). Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-17. (Pubitemid 34094901)